Reactions: study looks at bone health in transgender youth on blockers and hormones
A study published in JAMA Pediatrics has analysed bone density in 75 transgender youth who underwent hormone blockade in adolescence, followed by hormone treatment.
Specialist in Family and Community Medicine and member of the LGTBIQ+ Health Group of the Madrid Society of Family and Community Medicine
A study published in JAMA Pediatrics has analysed bone density in 75 transgender youth who underwent hormone blockade in adolescence, followed by hormone treatment.
An analysis of data published in the journal General Psychiatry with more than 66,000 diagnoses of gender dysphoria, mostly made in the United States, concludes that prevalence increased between 2017 and 2021, and that the median age decreased over the same period from 31 to 26 years.
A study published in NEJM that followed a cohort of more than 300 transgender and non-binary youth, aged 12-20, for two years concluded that hormone therapy led to improvements in their symptoms of depression and anxiety.
A study of hospitalised young people in the United States concludes that those with a diagnosis of gender dysphoria are four to five times more likely to be hospitalised for a suicide attempt or to have attempted self-harm. The research is published in The Lancet Child & Adolescent Health.
A study published in The Lancet Child & Adolescent Health shows that 98% of a cohort of trans adolescents in the Netherlands who started hormone treatment before adolescence continued to do so years later.